T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

• John Timmerman,
• David Lavie,
• Nathalie A. Johnson,
• Abraham Avigdor,
• Peter Borchmann,
• Charalambos Andreadis,
• Ali Bazargan,
• Gareth Gregory,
• Colm Keane,
• Inna Tzoran,
• Vladan Vucinic,
• Pier Luigi Zinzani,
• Hong Zhang,
• Pallavi Pillai,
• Akash Nahar,
• Alex F. Herrera

Affiliations

John Timmerman

1 UCLA Medical Center, Los Angeles, CA, USA

David Lavie

2 Hadassah Medical Center, Jerusalem, Israel

Nathalie A. Johnson

3 Jewish General Hospital, Montreal, QC, Canada

Abraham Avigdor

4 Sheba Medical Center–Tel HaShomer, Ramat Gan, Israel

Peter Borchmann

6 University Hospital of Cologne, Cologne, Germany

Charalambos Andreadis

7 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Ali Bazargan

8 University of Melbourne, Melbourne, VIC, Australia

Gareth Gregory

10 School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia

Colm Keane

11 Princess Alexandra Hospital, Brisbane, QLD, Australia

Inna Tzoran

12 Rambam Health Care Campus, Haifa, Israel

Vladan Vucinic

13 University of Leipzig Medical Center, Leipzig, Germany

Pier Luigi Zinzani

14 IRCCS-University of Bologna Seragnoli Institute of Hematology and Department of Specialized, Diagnostic, and Experimental Medicine, University of Bologna, Bologna, Italy

Hong Zhang

15 Merck & Co., Inc., Rahway, NJ, USA

Pallavi Pillai

15 Merck & Co., Inc., Rahway, NJ, USA

Akash Nahar

15 Merck & Co., Inc., Rahway, NJ, USA

Alex F. Herrera

16 City of Hope, Duarte, CA, USA